Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment
- PMID: 12539090
- DOI: 10.1086/345746
Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment
Abstract
Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
